RDIF, Rusatom subsidiary, AAMG to invest in nuclear medicine center in Malaysia
SINGAPORE. Nov 14 (Interfax) - The Russian Direct Investment Fund (RDIF), Singapore's Asian American Medical Group (AAMG) and JSC Rusatom Healthcare, a subsidiary of Russian state nuclear corporation Rosatom, have agreed to jointly develop a nuclear medicine center in Iskandar Puteri, Malaysia, the RDIF said in a press release.
The agreement was signed on the sidelines of a meeting between Russian President Vladimir Putin and Singapore's Prime Minister Lee Hsien Loong.
The proposed project involves the creation of a modern medical institution specializing in the diagnosis and treatment of cancer. The center, neighboring Singapore, will include departments specializing in radionuclide diagnostics, radionuclide therapy, radiation therapy and a cyclotron based radiochemistry facility among others.
The project will combine the financial resources of RDIF and Rosatom and technical expertise of Rosatom - which specializes in domestic and international promotion of Russian nuclear technology for medicine - with AAMG, a healthcare specialist based in Singapore which is listed on the Australian Securities Exchange.
"Nuclear medicine is a promising high-tech specialty for the diagnosis and treatment of cancer. In Russia, this area is rapidly developing, and the expanded use of Russian technologies abroad supports this development. We are pleased to be able to support this process by implementing a project to build a nuclear medicine center in Malaysia. This will ensure the export of Russian technologies and support Rosatom's entry to the international market," said Kirill Dmitriev, CEO of the RDIF.